ABVC BIOPHARMA, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $296,000 | $0 | $152,430 | $969,783 | $355,797 |
| Cost of revenue | — | $763 | $302,037 | $286,415 | $5,086 |
| Gross profit | — | $508,826 | -$149,607 | $683,368 | $350,711 |
| Selling, general & administrative | $2.9M | $2.3M | $5.4M | $6.1M | $5.7M |
| Research and development | $121,085 | $179,272 | $1.1M | $2.7M | $1.0M |
| Operating expenses | $7.2M | $5.2M | $6.6M | $15.8M | $12.1M |
| Operating income | -$7.2M | -$4.7M | -$6.8M | -$15.1M | -$11.7M |
| Interest expense | $415,890 | $825,899 | $1.3M | $293,968 | $227,210 |
| Pretax income | -$8.4M | -$5.4M | -$8.0M | -$15.5M | -$11.2M |
| Income tax expense | $24,154 | -$110,539 | $256,006 | $797,778 | $825,024 |
| Net income | -$7.9M | -$4.9M | -$7.8M | -$16.4M | -$12.8M |
| Balance Sheet | |||||
| Cash and equivalents | $681,480 | $248,382 | $60,155 | $85,265 | $5.8M |
| Current assets | $2.5M | $2.2M | $1.7M | $3.0M | $7.7M |
| Total assets | $21.1M | $7.5M | $7.8M | $9.6M | $13.7M |
| Current liabilities | $6.2M | $6.6M | $6.1M | $5.5M | $3.7M |
| Total liabilities | $7.8M | $6.8M | $6.5M | $6.3M | $4.8M |
| Stockholders' equity | $11.1M | $1.2M | $1.6M | $3.1M | $8.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$3.0M | -$1.8M | -$4.2M | -$7.4M | -$7.6M |
| Depreciation and amortization | $25,330 | $32,025 | $28,531 | $23,799 | $11,993 |
| Stock-based compensation | $4.1M | $2.8M | $185,933 | $7.0M | $5.3M |
| Capital expenditure | $37.0M | — | $21,201 | $119,692 | $17,503 |
| Free cash flow | -$40.0M | — | -$4.2M | -$7.5M | -$7.6M |
| Share repurchases | — | $7,320 | — | — | — |
| Impairments | — | — | — | $110,125 | $741,390 |
Shares outstanding 26.0M
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.